Elidel

Quick links to important sections

Elidel

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elidel

Property Description
Active Ingredient Pimecrolimus
Form Cream (Topical Preparation)
Pharmacological Class Topical Calcineurin Inhibitor (TCI)
General Purpose Provides anti-inflammatory and immune-calming effects
Origin Synthetic Macrolactam Derivative

What Type of Medicine is Elidel (Pimecrolimus)?

Elidel is a prescription-only medication known for its active ingredient, Pimecrolimus, which is a synthetic non-steroidal agent that functions as an immunomodulator. It belongs to the specialized pharmacological class of Topical Calcineurin Inhibitors (TCIs), a classification that is clinically recognized for providing targeted immune response modification.

Pimecrolimus is chemically classified as a macrolactam derivative of the compound ascomycin, which defines its unique molecular structure compared to traditional anti-inflammatory agents. This TCI classification is a differentiating factor, marking it as a precision treatment for immune-driven skin reactions.

Composition and General Therapeutic Purpose

Elidel is consistently formulated as a single-ingredient cream for topical application. This preparation, which features Pimecrolimus suspended in an emulsion-based vehicle, is designed to maximize local delivery of the active component while maintaining good patient acceptance.

The general therapeutic purpose of Elidel is to provide a reliable anti-inflammatory effect by selectively calming the hyperactivity of skin immune cells. This effect is supported by pharmacological studies confirming that Pimecrolimus specifically inhibits the enzyme calcineurin, thereby halting the cellular processes that lead to the sustained release of cytokines and other inflammatory mediators. Consequently, the medicine is used to alleviate the general irritation, redness, and discomfort associated with localized skin immune overreactions.

Regulatory References

  1. NIH - StatPearls - Pimecrolimus

What side effects are possible with Elidel?

Possible Side Effects and Safety Information

The safety profile of Elidel (pimecrolimus) cream is based on classifications from government regulatory authorities and primarily involves localized adverse reactions and specific constraints regarding infectious risk.

Frequency Classification of Adverse Reactions

The most frequently documented side effects are typically confined to the application site and are classified by frequency:

  • Very Common (affecting more than 1 in 10 patients): Burning sensation at the application site.
  • Common (affecting 1 to 10 in 100 patients): Application site irritation, redness (erythema), itching (pruritus), and folliculitis. These localized reactions are most often observed at the start of treatment and are generally transient.
  • Uncommon: Skin infections, including herpes simplex, molluscum contagiosum, and impetigo. Other uncommon effects include rash and numbness or tingling (paraesthesia).
  • Rare: Alcohol intolerance, manifesting as facial flushing or skin irritation, and hives (urticaria).

Serious Adverse Reactions and Regulatory Constraints

Official regulatory documents note rare cases of lymphoma and skin malignancy in patients using topical calcineurin inhibitors. While a definitive causal link has not been established, this concern informs the safety constraint against continuous, long-term use. Very rare cases of anaphylactic reactions have also been reported.

Population and Administration Safety Notes

Regulatory labeling contains explicit constraints for specific patient populations. The safety and effectiveness of the cream have not been established in children under 2 years of age. Furthermore, use is not recommended in patients who are immunocompromised or in areas with acute cutaneous viral infections.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents address the overdose profile of Elidel (pimecrolimus) cream primarily in the context of accidental oral ingestion, rather than excessive use on the skin. Due to the minimal systemic absorption observed following topical application, regulatory labeling does not formally specify a distinct set of symptoms or a toxicity profile for applying too much cream to the skin.


Required Emergency Actions

If accidental oral ingestion of the cream occurs, the official guidance is to seek immediate medical attention or contact emergency services immediately. This instruction applies to all patients, including pediatric patients, in whom accidental ingestion is noted as a possibility. Regulatory documents provide a specific procedural directive: vomiting should not be induced following the swallowing of the cream. In cases of significant ingestion, management may include procedural measures such as gastric lavage, as determined by a healthcare professional.


Management Constraints

A key constraint noted in the official prescribing information is that no specific antidote is known for pimecrolimus. Therefore, the required clinical treatment for an overdose is restricted to being strictly symptomatic and supportive, addressing only the manifestations that occur.

Therapeutic Uses of Elidel

Quick Facts About Elidel Uses

  • Therapeutic Domain: Mild to moderate atopic dermatitis (eczema).
  • Patient Population: Adults and children aged 2 years and older.
  • Treatment Context: Second-line therapy for short-term and non-continuous chronic use.
  • Goal of Therapy: Supports the management of symptoms, including rash, redness, and itching.

What Elidel Treats: Main Uses and Benefits

Elidel (pimecrolimus) cream is a prescription topical treatment indicated for the management of mild to moderate atopic dermatitis, commonly known as eczema. This treatment is intended for use in adults and children who are 2 years of age and older.

The medication is utilized as a second-line therapy for patients who have not responded adequately to other topical prescription treatments or when the use of those treatments is not medically recommended. Its application is for short-term management and for intermittent, non-continuous chronic treatment.

The core function of the cream is to help relieve the signs and symptoms associated with atopic dermatitis, which typically include skin inflammation, redness, and pruritus (itching). The treatment aims to support the resolution of visible symptoms on the skin.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Elidel — Official Regulatory Information

This section is strictly based on the population-eligibility rules, restrictions, and contraindications defined in authoritative governmental regulatory documents (e.g., US FDA, EMA, and national health authorities).


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and children 2 years of age and older who are non-immunocompromised and who failed to respond adequately to other topical prescription treatments.
Populations for whom use is not recommended Immunocompromised adults and children (including those on systemic immunosuppressive medications) and patients with Netherton's Syndrome or generalized erythroderma.
Populations for whom use is contraindicated Individuals with a history of hypersensitivity to pimecrolimus, other macrolactams, or any of the cream's components.
Age-related eligibility rules Not indicated for use in children less than 2 years of age (US FDA). Use in older adults (65 and over) has insufficient data for comparison to younger patients.
Condition-specific eligibility rules Use should not be applied to areas of active cutaneous viral infections (e.g., herpes simplex) or to potentially malignant skin lesions.
Pregnancy and lactation eligibility status Pregnancy Category C (US FDA): Use only if the benefit justifies the potential risk to the fetus. Decision to discontinue breastfeeding or discontinue the drug must be made (Lactation).

Eligibility Classifications (High-Level)

Category Official Regulatory Statement
Eligibility severity classification Officially categorized as Contraindicated (Hypersensitivity), Not Indicated (Children < 2), and Not Recommended (Immunocompromised).
Eligibility-context constraints Use is strictly limited to short-term and non-continuous chronic treatment in any age group.

Connection to the overall eligibility profile

Regulatory documents establish that Elidel use is limited to patients 2 years of age and older who are not immunocompromised and are using the medication non-continuously. The profile rigorously prohibits use for those with a known hypersensitivity and formally restricts it in specific conditions such as active viral skin infections and for individuals with Netherton's Syndrome. These strict rules define the population authorized to use the drug and those who are expressly excluded based on official regulatory findings.

What should I know about interactions with other medicines?

Elidel Interactions with other medicines and products

Official regulatory documents define the product's interaction structure primarily by establishing that systemic drug–drug interactions are unlikely due to the minimal systemic absorption of pimecrolimus.


Pharmacokinetic and Exposure Constraints

Classification Official Regulatory Statement
Metabolic Basis Pimecrolimus is exclusively metabolised by CYP 450 3A4.
Exposure Likelihood Systemic interactions with co-administered medicines are formally stated as unlikely to occur due to minimal absorption.
Interacting Medicines Strong CYP3A4 inhibitors (e.g., azole antifungals) may theoretically increase plasma concentrations. Co-use with systemic antibiotics, antihistamines, and corticosteroids is generally acceptable.

Procedural and Substance Restrictions

Restriction Type Official Regulatory Statement
Systemic Co-therapy Use with systemic immunosuppressive therapies (like azathioprine or ciclosporin A) has not been studied and is not recommended.
Phototherapy Excessive exposure to ultraviolet light (UVA, UVB, or solarium) must be avoided during treatment.
Alcohol A pharmacodynamic interaction is documented: flushing, rash, or burning have been observed shortly after the intake of alcohol in some patients.
Timing Rule Vaccinations should be administered during treatment-free intervals for patients with extensive disease, and the cream must be avoided on vaccination sites while local reactions persist.

Mechanism of Action

How Elidel Works: The Mechanism of Action

The mechanism of Pimecrolimus is defined by its highly targeted action on the Calcineurin pathway, which is central to activating key immune cells. The drug acts as an immunomodulator, suppressing core biochemical signals that regulate cellular activation.


1. Inhibition of T-Cell Signaling via Calcineurin

Pimecrolimus exerts its effect by binding to the cellular protein Macrophilin-12 (FKBP-12), forming a complex that directly inhibits the enzyme Calcineurin. This disruption stops Calcineurin from activating the transcription factor NFAT (Nuclear Factor of Activated T cells), which is essential for T-cells to fully activate and proliferate. This molecular cascade ultimately results in the suppression of cytokine synthesis, thereby reducing downstream signaling activity.


2. Dampening Mediator Release and Localized Immune Response

The drug's mechanism extends beyond T-cells; it also targets mast cells, inhibiting the release of preformed inflammatory mediators like histamine and serotonin. This two-fold action—blocking T-cell programming and mast cell degranulation—is crucial. The physiological consequence is a reduction in the total concentration of pro-inflammatory chemicals, resulting in the localized modulation of the immune response.

Dosage and Administration Information

How to Use Elidel (Pimecrolimus) Cream

Elidel (pimecrolimus) cream, 1%, is a prescription topical medicine for external use only. The administration protocol is established to standardize use in clinical practice.


Official Administration Guidelines

Category Instruction
Route of Administration Topical application to the skin.
Approved Strength 1% cream concentration.
Dosing Frequency Twice daily application.
Labeled Dosing Rule Apply a thin layer to the affected areas, using the smallest amount necessary to cover the skin surface.

Duration and Usage Context

The treatment duration is structurally defined as short-term management. For patients with a chronic condition, the medicine is used for intermittent, non-continuous chronic treatment, meaning application is restricted to specific periods to manage symptoms rather than perpetual daily use.

Administration must be initiated at the first signs of symptoms of atopic dermatitis. Treatment should be discontinued immediately when the signs and symptoms clear and should not continue past a maximum of six weeks if no improvement is seen.

Population and Procedural Constraints

Elidel is approved for use in adults and children 2 years of age and older. It is not intended for use in pediatric patients under two years of age. The official instructions explicitly restrict the concurrent use of the cream with occlusive dressings (such as bandages or wraps) over the treatment area, as this may impact its proper function.

If a dose is missed, it should be applied as soon as possible, and then the patient should resume the regular twice-daily schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Elidel


Evidence for Short-Term Management of Mild to Moderate Eczema

Research evidence for the early use of pimecrolimus cream primarily consists of short-term Randomized Controlled Trials (RCTs) conducted during periods of increased symptom activity. These studies examined patient populations of adults and children aged 2 years and older to examine outcomes related to the signs and symptoms of atopic dermatitis. Researchers monitored clinical metrics using standard scales, such as the Investigator’s Global Assessment (IGA) score, and collected data on changes in disease severity and extent over short, defined time intervals, typically lasting a few weeks.

Initial research explored outcomes by comparing the active cream against the inactive cream base (known as the vehicle). These studies reported data collected on how symptoms evolved, noting measurements taken during the short study period. However, the follow-up durations for these initial comparative trials were brief, and comparative evidence against other active prescription creams is lacking in these initial trials.


Long-Term Evidence for Disease Control and Flare Prevention

To explore outcomes over an extended duration for this condition, research has monitored patient data over extended periods using both long-term RCTs and large, regulator-mandated post-marketing observational registry studies. These studies collected data on outcomes related to systemic or functional patterns over 6 months to several years. Research examined the use of the cream in conditions characterized by fluctuating or episodic manifestations, focusing on the outcomes of intermittent and non-continuous use of the cream on long-term symptom patterns and the frequency of eczema flare-ups.

Findings describe patterns observed related to the presence or absence of disease activity and the duration between exacerbations (flares). Studies reported measurements of the use of topical corticosteroid medications when compared to control groups over the observed time periods.

Long-term outcomes remain subjects of continued research, and lengthy post-marketing studies have been implemented to collect further data. Comparative evidence against every alternative chronic management strategy is not fully characterized, and research provides context but not individual predictions about long-term success.


Research Findings for Use in Specific Age Groups

Studies explored the use of pimecrolimus cream in children aged 2 years and older, forming a key part of the overall evidence base. Additionally, specific trials were conducted in the population of infants and toddlers aged 3 to 23 months with mild to moderate disease.

For infants and very young children, clinical data reported how symptoms evolved, describing changes measured in terms of overall skin condition. However, trial findings indicated some differences in this group; specific reports noted differences in the systemic presence of the medication compared to data from older populations. Furthermore, research observed an increased incidence of certain viral infections in some studies among the infants compared to the inactive control group.


What is Still Uncertain in the Research Landscape

One key area is the need for continued long-term data collection, particularly concerning potential rare occurrences over many years of intermittent use. Long-term outcomes are not fully established, and lengthy post-marketing studies have been required to collect further data. Furthermore, research highlights what is known and what is still uncertain regarding comparative evidence against every available prescription alternative.

Frequently Asked Questions (FAQ)

Common questions about Elidel (FAQ)


Q: How quickly does Elidel cream start to work for eczema?

Official clinical studies suggest that patients may begin to see initial signs of effectiveness within the first week of treatment. Patients may experience continued improvement as treatment progresses, but individual responses vary. Regulatory instructions advise that treatment should be stopped if no improvement is seen after six weeks.


Q: Can Elidel be used on the face, like around the eyes or mouth?

Elidel is approved for topical use on the skin, which includes affected areas on the head and neck. However, the official product information advises caution to ensure the cream is not applied to mucous membranes, such as the inside of the nose, the mouth, or the eyes.


Q: Can Elidel be used for skin conditions other than eczema?

No, official regulatory documents state that Elidel cream is indicated only for the short-term and intermittent long-term treatment of mild to moderate atopic dermatitis, which is the specific medical term for eczema.


Q: Why is Elidel sometimes prescribed instead of a topical steroid?

Official guidance indicates that Elidel (pimecrolimus) is often considered for patients who have not responded adequately to other prescription topical therapies. As a non-steroidal immunomodulator, it offers an alternative treatment approach for managing mild to moderate atopic dermatitis.


Q: Can I apply makeup or other products over Elidel cream?

The official instructions restrict the use of occlusive dressings (such as bandages or wraps) over the treatment area. Regulatory documents state that normal clothing can be worn over the treated area, but the product labeling does not provide specific guidance regarding the application of cosmetics, such as makeup.


Q: Is Elidel safe for long-term or chronic eczema management?

Official regulatory guidance emphasizes that Elidel is for short-term use and intermittent, non-continuous chronic treatment. Due to safety constraints, continuous long-term use should be avoided, and application should stop as soon as symptoms have cleared.


Q: Is it normal to feel a burning sensation when first applying Elidel?

Yes, a burning sensation at the application site is listed in regulatory documents as a very common side effect. This local irritation is most often reported at the very beginning of the treatment period and is generally expected to be transient (temporary).


Q: Why do doctors mention a potential risk of cancer with Elidel?

Official product labeling, including the FDA's Boxed Warning, notes that rare cases of lymphoma and skin malignancy have been reported in patients using topical calcineurin inhibitors. While a definitive causal link has not been established, this information informs the regulatory constraint against continuous, long-term use.


Q: How soon after starting Elidel do I need to see improvement?

Treatment should be discontinued and the diagnosis re-evaluated by a healthcare provider if the skin condition does not show improvement after a maximum of six weeks of use. This is the official benchmark for assessing whether the medication is working.


Q: What happens if I forget to apply a dose of Elidel?

Official instructions advise applying the missed dose as soon as it is remembered and then resuming the regular schedule. Regulatory guidance specifies against doubling the dose to compensate.


Q: Can pregnant women or those who are breastfeeding use Elidel?

The official product information lists the drug as Pregnancy Category C, meaning its use is only justified if the potential benefit outweighs the potential risk. For breastfeeding, a decision must be made in consultation with a healthcare professional to either stop nursing or discontinue the use of the cream.


Q: Is it possible to have an allergic reaction to Elidel?

Yes, regulatory documents list hypersensitivity (an allergy) to pimecrolimus or any other component of the cream as a contraindication, meaning the drug should not be used. There have also been very rare reports of serious allergic reactions, such as anaphylaxis.


Q: Are there generic versions of Elidel available?

Yes, pimecrolimus cream, 1%, which contains the same active ingredient and strength as Elidel, is available as a generic drug equivalent.


Q: Is Elidel used for contact dermatitis or only atopic dermatitis?

Elidel is indicated only for the treatment of atopic dermatitis (eczema). The official regulatory information does not list contact dermatitis or other types of dermatitis as an approved use for the medication.


Q: Is Elidel effective for seborrheic dermatitis?

Official product labeling limits the indication for Elidel cream to the management of mild to moderate atopic dermatitis. The treatment of seborrheic dermatitis is not an officially approved use listed in regulatory documents.


Q: Does food or drink affect how Elidel works?

A specific interaction is documented regarding the intake of alcohol. In some patients, symptoms like facial flushing, a rash, or a burning sensation have been observed on the skin shortly after consuming alcohol while using the cream.


Q: How long does the tube of Elidel usually last for a typical user?

Regardless of how much cream is left in the tube, official storage requirements mandate that the cream must be discarded no later than 12 weeks (three months) after the tube is first opened. This is to ensure the stability and effectiveness of the medication.


Q: What does the drug's manufacturer say about the boxed warning for Elidel?

The FDA-approved product labeling includes a Boxed Warning that summarizes potential, rare, and serious risks of cancer (specifically skin cancer and lymphoma). This is the key reason why the use of the medication is restricted to short-term and intermittent treatment only.


Q: What should I do if my skin condition gets worse while using Elidel?

If your eczema symptoms worsen or if they fail to improve after using the medication for six weeks, official instructions state that you should stop treatment. The official instructions advise that the patient should be re-examined by a healthcare provider to confirm the diagnosis and determine the next treatment steps.


Q: What are the ingredients in Elidel besides the active one?

The cream base contains the inactive ingredients necessary to form the preparation. These include substances like benzyl alcohol, cetyl alcohol, stearyl alcohol, propylene glycol, oleyl alcohol, citric acid, sodium cetostearyl sulfate, and sodium hydroxide.


Q: Does stopping Elidel suddenly cause the eczema to flare up?

The official regulatory instructions specify that treatment should be discontinued immediately when the signs and symptoms of eczema clear. The product labeling does not contain specific warnings about a discontinuation syndrome or a rebound flare-up upon stopping the medication.


Q: Are people who use Elidel more prone to skin infections?

Uncommon side effects reported in regulatory documents include various skin infections, such as herpes simplex, molluscum contagiosum, and impetigo. The cream should not be applied to areas of the skin with active viral infections.


Q: Does Elidel make your skin more sensitive to heat or cold?

The official safety information does not specifically list increased sensitivity to environmental heat or cold as an adverse effect. However, some patients have reported warmth or flushing in the skin associated with concurrent alcohol intake.


Q: What should I avoid doing while I have Elidel on my skin?

Regulatory warnings state that excessive exposure to ultraviolet light (UV), such as from the sun or tanning beds, and the use of occlusive dressings (bandages or wraps) over the treated area must be avoided.


Q: Is Elidel known to cause skin discoloration or lightening?

Rare reports of pigmentation changes have been documented in official product information. These changes include both hypopigmentation (skin lightening) and hyperpigmentation (skin darkening) in the treated areas.


Q: Does sun exposure make Elidel side effects worse?

Official warnings state that patients should avoid or limit sun exposure during treatment. The label specifies that it is currently not known how the cream may affect the skin when exposed to ultraviolet light, leading to the strict cautionary recommendation.

How should Elidel be stored and disposed of?

Official Storage and Disposal Requirements for Elidel Cream

Elidel (pimecrolimus) cream must be stored according to specific regulatory requirements to ensure stability and safety.

Storage Conditions

Requirement Details
Temperature Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F). Do not store above 25 C.
Prohibitions Do not freeze. Store away from excess heat and moisture (e.g., avoid the bathroom).
Packaging Keep the tube in its original carton and the container tightly closed.
In-Use Stability Discard the cream no later than 12 weeks (3 months) after the tube is first opened.
Child Safety Keep the medication out of the reach and sight of children.
Handling Warning: Fabrics (clothing, bedding, etc.) that have been in contact with Elidel cream burn more easily and should be kept away from naked flames.

Disposal Instructions

Unused or expired Elidel Cream should not be disposed of in household trash or wastewater. Return the outdated medication to a pharmacist or follow local community collection guidelines for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Elidel found in:

A-Z Index: